Drivers of Therapy Selection in Metastatic Gastric Cancer
Survey Objectives
Assess differences in prescribing patterns of FOLFIRI and LONSURF in the setting of metastatic gastric cancer (mGC).
Identify the differences in therapy decision making between these two therapies, especially with regards to patient clinical factors In February, twenty-two medical oncologists across Canada who treat mGC answered the survey. Below are some key findings.
Goals of therapy
For survey respondents who prescribed FOLFIRI for mGC patients in the last six months, the most common goals of therapy were palliation and survival. For survey respondents who prescribed LONSURF for mGC patients in the last six months, the most common goals of therapy were palliation and disease control.
Line of therapy
All but one survey respondent prescribed FOLFIRI in the last six months. Half of the respondents prescribed LONSURF in the past six months. FOLFIRI and LONSURF use is focused in second and third line mGC treatment, respectively.
The most common factors driving FOLFIRI use are its tolerability and patient disease progression. For LONSURF, its oral administration and tolerability were the most common factors.
Share your thoughts on these two questions:
Respondents report 11% of mGC patients prescribed LONSURF go on to an additional line of therapy. In your opinion, what percent of mGC patients treated with FOLFIRI go on to an additional line of therapy?
What do you find interesting about the survey results?
